Ocera Therapeutics (OCRX) Receives Daily Media Sentiment Score of 0.18

Media stories about Ocera Therapeutics (NASDAQ:OCRX) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ocera Therapeutics earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.0365107911928 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

OCRX has been the topic of a number of recent research reports. Cowen reiterated a “buy” rating and set a $11.00 price target on shares of Ocera Therapeutics in a research note on Monday, December 18th. HC Wainwright lowered shares of Ocera Therapeutics from a “buy” rating to a “neutral” rating and set a $1.75 price target on the stock. in a research note on Friday, November 3rd. Finally, Zacks Investment Research lowered shares of Ocera Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $3.55.

Shares of Ocera Therapeutics (NASDAQ:OCRX) opened at $1.79 on Friday. The stock has a market cap of $47.46, a PE ratio of -1.85 and a beta of 2.46. Ocera Therapeutics has a one year low of $0.52 and a one year high of $2.95.

Ocera Therapeutics (NASDAQ:OCRX) last released its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.24). analysts expect that Ocera Therapeutics will post -0.93 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Ocera Therapeutics (OCRX) Receives Daily Media Sentiment Score of 0.18” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/12/30/ocera-therapeutics-ocrx-receives-daily-media-sentiment-score-of-0-18.html.

About Ocera Therapeutics

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Insider Buying and Selling by Quarter for Ocera Therapeutics (NASDAQ:OCRX)

Receive News & Ratings for Ocera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit